NCT04159155: CAN-STAMP

A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

Terminated Phase 2, PHASE3 Last updated 12 August 2025

What this trial tests

Phase 2, PHASE3 trial testing External Beam Radiation in Endometrial Carcinoma in 11 participants. Terminated before completion.

Timeline

17 November 2020

Primary endpoint
26 May 2025

26 May 2025

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	Phase 2, PHASE3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	17 November 2020
Primary completion	26 May 2025
Estimated completion	26 May 2025
Sites	1 location across Canada

Drugs / interventions tested

• External Beam Radiation — full drug profile →
• Niraparib (niraparib) — full drug profile →
• Vaginal high-dose rate brachytherapy
• Observation - no drugs

Conditions studied

• Endometrial Carcinoma — all drugs for Endometrial Carcinoma →
• P53 Mutation — all drugs for P53 Mutation →
• Serous Carcinoma — all drugs for Serous Carcinoma →

Sponsor

University Health Network, Toronto

Who can join

18 and older, female only, with Endometrial Carcinoma or P53 Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an umbrella, two-arm, multi-stage, phase II trial. The purpose of the trial in the early stage cohort is to determine if EBRT improves disease free survival (defined as the time from random assignment to disease recurrence or death from any cause) compared to vaginal brachytherapy after chemotherapy in women with serous or p53 aberrant endometrial cancer. The purpose of the trial in the advanced stage cohort is to determine if the maintenance with experimental treatment increases progression free survival, defined as the time from random assignment to disease progression or death from any cause.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Endometrial Cancer: Transitioning from Histology to Genomics.
   Mitric C, Bernardini MQ. · · 2022 · cited 37× · PMID 35200562 · DOI 10.3390/curroncol29020063
2. Translating biological insights into improved management of endometrial cancer.
   How JA, Jazaeri AA, Westin SN, Lawson BC, et al · · 2024 · cited 25× · PMID 39198622 · DOI 10.1038/s41571-024-00934-7
3. Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
   Madariaga A, Garg S, Tchrakian N, Dhani NC, et al · · 2023 · cited 22× · PMID 36922497 · DOI 10.1038/s41467-023-37084-w
4. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
   Jamieson A, Sobral de Barros J, Cochrane DR, Douglas JM, et al · · 2024 · cited 15× · PMID 38536067 · DOI 10.1158/1078-0432.ccr-23-3689
5. Current insights and future directions of Li-Fraumeni syndrome.
   Hosseini MS. · · 2024 · cited 7× · PMID 39404911 · DOI 10.1007/s12672-024-01435-w
6. Moving into the modern era of molecular classification for endometrial cancer.
   Dagher C, Liu YL, Mueller JJ, Weigelt B. · · 2024 · cited 7× · PMID 38100711 · DOI 10.1002/jso.27552
7. Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.
   Joly F, Leary A, Ray-Coquard I, Asselain B, et al · · 2025 · cited 5× · PMID 40858558 · DOI 10.1038/s41467-025-62678-x
8. Drug discovery in advanced and recurrent endometrial cancer: Recent advances.
   Francoeur AA, Ayoub N, Greenberg D, Tewari KS. · · 2025 · cited 4× · PMID 40612873 · DOI 10.32604/or.2025.061120